Agenus Inc. (AGEN) Stock Performance Overview
Closing Price (24 h period ending 05:59 PM CET, Thursday 22 Feb 2026):
The share price declined by 0.31 %.
Current trading price: USD 6.47 on major exchanges.
Trading Volume & Market Capitalisation:
Total shares outstanding: 45 million.
Market capitalisation: USD 289 million.
Volume traded in the last 24 h: USD 5.1 million.
Historical Performance:
Since the close of the previous month: -26.44 %.
Simple moving average (200 days): USD 4.84.
52‑week high: USD 10.31 (30 Sep 2026).
52‑week low: USD 2.71 (5 Feb 2026).
Comparative Performance of Related Biotech Shares (Last 24 h)
| Ticker | Recent Change | Current Price | Market Capitalisation |
|---|---|---|---|
| Xerox (XRX) | +4.98 % | USD 2.79 | USD 342.7 million |
| Vtv Therapeutics (VTVT) | -0.27 % | USD 27.54 | USD 346 million |
| Galectin Therapeutics (GALT) | -1.75 % | USD 3.41 | USD 345.9 million |
| Imricor Medical (IMR.AX) | -2.18 % | AUD 1.34 | AUD 493.1 million |
| Capricor Therapeutics (CAPR) | -11.04 % | USD 6.24 | USD 343.9 million |
Company Profile
Agenus Inc. is a biotechnology firm focused on immuno‑oncology. The company operates primarily from Lexington, United States, and develops checkpoint antibody therapies along with complementary agents to improve patient outcomes worldwide. Agenus’s shares are listed on the Nasdaq. The company completed its initial public offering on 4 February 2000. More information can be accessed at www.agenusbio.com .
